Adverse drug reactions to newer antidepressants

Adverse Drug Reaction Bulletin

Volumn , Issue 200, 2000, Pages 763-766

  Baldwin, David S ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ASTEMIZOLE; CIMETIDINE; CISAPRIDE; CITALOPRAM; CLOMIPRAMINE; CYCLOSPORIN; DOSULEPIN; EPHEDRINE; IMIPRAMINE; KETOCONAZOLE; LITHIUM; MAPROTILINE; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PETHIDINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TERFENADINE; TRAZODONE; TRIAZOLAM; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

CONSTIPATION; DEPRESSION; DIET RESTRICTION; DOSE RESPONSE; DROWSINESS; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERANCE; HEADACHE; HUMAN; NAUSEA; REVIEW; SEXUAL DYSFUNCTION; SLEEP DISORDER; SWEATING; VERTIGO; XEROSTOMIA;

EID: 0034004255     PISSN: 00446394     EISSN: None     Source Type: Journal    
DOI: 10.1097/00012995-200020000-00001     Document Type: Review

References (49)

1. Tyrer SP. Adverse reactions to drugs used in the treatment and prophylaxis of depression and mania. Adverse Drug Reaction Bulletin 1993; 160: 603-06.
2. Lane RM. A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction: incidence, possible aetiology and implications for management. Journal of Psychopharmacology 1997; 11: 72-82.
3. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. Journal of Clinical Psychopharmacology 1996; 16: 356-62.
4. Baldwin DS, Rudge SE. Moclobemide - a reversible inhibitor of monoamine oxidase type A. British Journal of Hospital Medicine 1993; 49: 497-9.
5. Hilton S, Jaber B, Ruch R. Moclobemide safety: monitoring a newly developed product in the 1990s. Journal of Clinical Psychopharmacology 1995: 15 (supplement 2): 76-83S.
6. Dingemanse J, Wood N, Guentert T, Oie S, Ouwerker M, Amrein R. Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects. Psychopharmacology 1998; 140: 164-72.
7. Dingemanse J, Guentert T, Gieschke R, Stabl M. Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase-A inhibitor moclobemide. Journal of Cardiovascular Pharmacology 1996; 28: 856-61.
8. Livingston MG, Livingston HM. Monoamine oxidase inhibitors. An update on drug interactions. Drug Safety 1996; 14: 219-27.
9. Baldwin DS, Rudge SE. Tolerability of moclobemide. Reviews in Contemporary Pharmacotherapy 1994; 5: 57-65.
10. Philipp M, Delini-Stula A, Baier D. Assessment of sexual dysfunction in depressed patients and reporting attitudes in routine daily practice: results of the postmarketing observational studies with moclobemide, a reversible MAO-A inhibitor. International Journal of Psychiatry in Clinical Practice 1999; 3: 257-64.
11. Gillman PK. Possible serotonin syndrome with moclobemide and pethidine. Medical Journal of Australia 1995; 162: 554.
12. Lane R, Baldwin DS. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. Journal of Clinical Psychopharmacology 1997; 17: 208-21.
13. Neuvonen PJ, Pohjola-Sintonen S, Tacke U, Vuori E. Five fatal cases of serotonin syndrome after moclobemide-eitalopram or moclobemide-clomipramine overdoses. Lancet 1993; 342: 1419.
14. Singer PP, Jones GR. An uncommon fatality due to moclobemide and paroxetine. Journal of Analytical Toxicology 1997; 21: 518-20.
15. Eison AS, Eison MS, Torrente JR, Wright RN, Yocca FD. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacology Bulletin 1990; 26: 311-15.
16. Marcus RN. Safety and tolerability profile of nefazodone. Journal of Psychopharmacology 1996: 10 (supplement 1): 11-17.
17. Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline and venlafaxine. Journal of Clinical Psychiatry 1995; 56 (supplement 6) : 12-21.
18. Robinson DS, Roberts DL, Smith JC, et al. The safety profile of nefazodone. Journal of Clinical Psychiatry 1996; 57 (supplement 2): 31-8.
19. Feiger A, Kiev A, Shrivastava RK, Wisselink PG, Wilcox CS. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability and effects on sexual function and satisfaction. Journal of Clinical Psychiatry 1996; 57 (supplement 2): 53-62.
20. Reynolds RD. Sertraline-induced anorgasmia treated with intermittent nefazodone. Journal of Clinical Psychiatry 1997; 58: 89.
21. Brodie-Meijer CC, Diemont WL, Buijs PJ. Nefazodone-induced clitoral priapism. International Clinical Psychopharmacology 1999; 14: 257-8.
22. Eberstein S, Adler LA, Angrist B. Nefazodone and akathisia. Biological Psychiatry 1996; 40: 798-9.
23. Greenberg WM. Visual field 'shimmering' associated with nefazodone. Journal of Clinical Psychiatry 1999; 60: 124.
24. Owen JR, Nemeroff CB. New antidepressants and the cytochrome P450 System: focus on venlafaxine, nefazodone, and mirtazapine. Depression and Anxiety 1998; 7 (supplement 1): 24-32.
25. Vella JP, Sayegh MH. Interactions between cyclosporine and newer antidepressant medications. American Journal of Kidney Disease 1998; 31: 320-3.
26. Hawley CJ, Sivakumaran T, Huber TJ, Ige AG. Combination therapy with nefazodone and lithium: safety and tolerability in fourteen patients. International Journal of Psychiatry in Clinical Practice 1998; 2: 251-4.
27. Aranda-Michel J, Koehler A, Bejarano PA, et al. Nefazodone-induced liver failure: report of three cases. Annals of Internal Medicine 1999; 130: 285-8.
28. Horst WD, Preskorn SH. The pharmacology and mode of action of venlafaxine. Reviews in Contemporary Pharmacotherapy 1998; 9: 293-302.
29. Baldwin DS. Venlafaxine. Prescribers' Journal 1999; 39: 242-7.
30. Sinclair JMA, Birtwistle J, Baldwin DS. The tolerability of venlafaxine. Reviews in Contemporary Pharmacotherapy 1998; 9: 333-4.
31. Russel JL. Relatively low doses of cisapride in the treatment of nausea in patients treated with venlafaxine for treatment-refractory depression. Journal of Clinical Psychopharmacology 1996; 16: 35-7.
32. Blythe D, Hackett LP, Cardiovascular and neurological toxicity of venlafaxine. Human Experimental Toxicology 1999; 18: 309-13.
33. Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine: analysis of the clinical trials database. Journal of Clinical Psychopharmacology 1996; 16 (supplement): 54-9S.
34. Fantaskey A, Burkhart KK. A case report of venlafaxine toxicity. Journal of Toxicology - Clinical Toxicology 1995; 33: 359-61.
35. Woo OF, Vredenburg M, Freitas P, et al. Seizures after venlafaxine overdose: a case report. Journal of Toxicology and Clinical Toxicology 1995; 33: 349-50.
36. Feighner JP. Cardiovascular safety in depressed patients: focus on venlafaxine. Journal of Clinical Psychiatry 1995; 56: 574-9.
37. West S, Hewitt J. Prolonged hypertension: a case report of a potential interaction between electroconvulsive therapy and venlafaxine. International Journal of Psychiatry in Clinical Practice 1999; 3: 55-7.
38. Nutt D. Mirtazapine: pharmacology in relation to adverse effects. Acta Psychiatrica Scandinavica Supplementum 1997; 391: 31-7.
39. Montgomery SA. Safety of mirtazapine: a review. International Clinical Psychopharmacology. 1995; 10 (supplement 4): 37-45.
40. Boyarsky BK, Haque W, Rouleau MR, Hirschfield RM. Sexual functioning in depressed outpatients taking mirtazapine. Depression and Anxiety 1999; 9: 175-9.
41. Kasper S, Praschak-Rieder N, Tauscher J, Wolf R. A risk-benefit assessment of mirtazapine in the treatment of depression. Drug Safety 1997; 17: 251-64.
42. Hoes MJ, Zeijpveld JH. First report of mirtazapine overdose. International Clinical Psychopharmacology 1996; 11: 147.
43. Bremner JD, Wingard P, Walshe TA. Safety of mirtazapine in overdose. Journal of Clinical Psychiatry 1998; 59: 233-5.
44. Baldwin DS, Carabal E. Reboxetine, a selective noradrenaline reuptake inhibitor for the treatment of depression. Drugs of Today 1999; 35: 719-24.
45. Mucci M. Reboxetine: a review of antidepressant tolerability. Journal of Psychopharmacology 1997; 11 (supplement 4): S33-7.
46. Anonymous. Reboxetine - another new antidepressant. Drugs and Therapeutics Bulletin 1998; 36: 86-8.
47. Szabadi E. Doxazosin for reboxetine-induced urinary hesitancy. British Journal of Psychiatry 1998; 173: 441-2.
48. Baldwin DS, Hawley CJ, Szabadi E, et al. Reboxetine in the treatment of depression: early clinical experience in the UK. International Journal of Psychiatry in Clinical Practice 1998; 2: 195-201.
49. Dostert P, Benedetti MS, Poggesi I. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline re-uptake inhibitor. European Neuropsychopharmacology 1997; 7 (supplement 1): S23-35.